JP7691977B2 - 抗ｔｉｒｃ７抗原結合タンパク質 - Google Patents

抗ｔｉｒｃ７抗原結合タンパク質 Download PDF

Info

Publication number
JP7691977B2
JP7691977B2 JP2022519994A JP2022519994A JP7691977B2 JP 7691977 B2 JP7691977 B2 JP 7691977B2 JP 2022519994 A JP2022519994 A JP 2022519994A JP 2022519994 A JP2022519994 A JP 2022519994A JP 7691977 B2 JP7691977 B2 JP 7691977B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
abp
tirc7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504974A (ja
JP2023504974A5 (https=
Inventor
ウツク，ナラン
Original Assignee
ネコナル エス．ア．エール．エル．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネコナル エス．ア．エール．エル． filed Critical ネコナル エス．ア．エール．エル．
Publication of JP2023504974A publication Critical patent/JP2023504974A/ja
Publication of JP2023504974A5 publication Critical patent/JP2023504974A5/ja
Application granted granted Critical
Publication of JP7691977B2 publication Critical patent/JP7691977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022519994A 2019-09-30 2020-09-30 抗ｔｉｒｃ７抗原結合タンパク質 Active JP7691977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200324 2019-09-30
EP19200324.2 2019-09-30
PCT/EP2020/077422 WO2021073877A2 (en) 2019-09-30 2020-09-30 Anti-tirc7 antigen binding proteins

Publications (3)

Publication Number Publication Date
JP2023504974A JP2023504974A (ja) 2023-02-08
JP2023504974A5 JP2023504974A5 (https=) 2023-09-05
JP7691977B2 true JP7691977B2 (ja) 2025-06-12

Family

ID=68084722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519994A Active JP7691977B2 (ja) 2019-09-30 2020-09-30 抗ｔｉｒｃ７抗原結合タンパク質

Country Status (6)

Country Link
US (2) US12497451B2 (https=)
EP (1) EP4041766A2 (https=)
JP (1) JP7691977B2 (https=)
AU (1) AU2020367945A1 (https=)
CA (1) CA3156134A1 (https=)
WO (1) WO2021073877A2 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525792A (ja) 2001-12-21 2005-09-02 ゲンパト７７ ファーマコジェネティクス エージー 免疫関連疾患および他の疾患に用いる治療的抗ｔｉｒｃ７抗体
JP2005531282A (ja) 2001-12-21 2005-10-20 ゲンパト７７ ファーマコジェネティクス エージー 炎症性疾患の治療に用いる抗ｔｉｒｃ７抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525792A (ja) 2001-12-21 2005-09-02 ゲンパト７７ ファーマコジェネティクス エージー 免疫関連疾患および他の疾患に用いる治療的抗ｔｉｒｃ７抗体
JP2005531282A (ja) 2001-12-21 2005-10-20 ゲンパト７７ ファーマコジェネティクス エージー 炎症性疾患の治療に用いる抗ｔｉｒｃ７抗体

Also Published As

Publication number Publication date
WO2021073877A3 (en) 2021-07-29
JP2023504974A (ja) 2023-02-08
CA3156134A1 (en) 2021-04-22
US20220363753A1 (en) 2022-11-17
AU2020367945A1 (en) 2022-05-12
WO2021073877A2 (en) 2021-04-22
EP4041766A2 (en) 2022-08-17
US12497451B2 (en) 2025-12-16
US20260062479A1 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
JP7577435B2 (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
TWI744242B (zh) Egfrviii及cd3抗體構築體
CN109476736B (zh) 结合间皮素和cd3的双特异性抗体构建体
TWI886677B (zh) 雙特異性抗體產品之連續製造製程
EA039594B1 (ru) Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
JP2020504105A (ja) 新規なｔｎｆｒアゴニストおよびその使用
KR20180033501A (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
JP7495409B2 (ja) 改善された抗ｆｌｔ３抗原結合タンパク質
KR20150093744A (ko) Bcma 항원 결합 단백질
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
TWI870360B (zh) 雙特異性抗體構建體之下游加工
JP7691977B2 (ja) 抗ｔｉｒｃ７抗原結合タンパク質
EP3623383A1 (en) Improved bispecific flt3xcd3 antigen binding proteins
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
RU2830982C2 (ru) Улучшенные анти-flt3 антигенсвязывающие белки
WO2025152912A1 (en) Cd98hc antigen-binding protein and use thereof
CA3111462C (en) Improved anti-flt3 antigen binding proteins
WO2025119330A1 (zh) 氨基酸接头结合分子及其用途
JP2025533434A (ja) 二重特異性分子安定化組成物
HK40096481A (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250602

R150 Certificate of patent or registration of utility model

Ref document number: 7691977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150